Only first 10,000 results will be saved in the file.
No item is selected. Use checkboxes to select search results.
Displaying 1-1 of 1 results.
{{ selectedCountPage }} items selected on this page,{{ selectedCountPage }} item selected on this page,{{ selectedCountTotal }} item in total{{ selectedCountTotal }} items in total
Study aim:
Evaluating the efficacy and safety of Ivermectin in the treatment of COVID-19 patients: A double-blind randomized controlled trial, phase II
Design:
Randomize double blind clinical trial, with control group, with a sample size of 60 people, with parallel groups, Phase 2 of Clinical trial
Settings and conduct:
The place of the study is Razi hospital and Sina hospital, Ahvaz university of medical science, simple sampling of patients with random allocation , double blind clinical trial, used drug and placebo, supervisor and participants are blind
Participants/Inclusion and exclusion criteria:
Inclusion criteria: Age ≥18 years, Laboratory polymerase chain reaction (PCR) confirmed infection with COVID19, Hospitalized, Satisfaction to participate in the study, Acceptance of non-participation in another study before the 28th day of the study. Exclusion criteria: Patients with a history of allergic reaction to Ivermectin Renal dysfunction Liver dysfunction Pregnancy or deciding to get pregnant or breastfeeding
Intervention groups:
Intervention group: Receive medication. One ivermectin 14 mg tablet every 12 hours for 3 days. Control group: placebo received a pill quite similar to Ivermectin every 12 hours for 3 days.
Main outcome variables:
virus polymerase reaction chain, Number of hospitalization days, hospitfever, dyspnea, , cough, chest CT scan, cell blood count, C-reactive protein